Comparable stake leader
Roger M. Klein
SEC ownership of Evoke Pharma Inc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001403708.
Disclosed value leader
Roger M. Klein
Comparable rows
4/6
Latest evidence
30 Nov 2025
- Parsed ownership sources
-
3/4/5 and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Roger M. Klein
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 6
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Roger M. Klein
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Nov 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001403708
- Issuer location
- Solana Beach, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Evoke Pharma Inc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Roger M. Klein
Disclosed value leader
Roger M. Klein
Comparable rows
4/6
Latest evidence
30 Nov 2025
3/4/5
13D/G
Lead comparable stake: 10%
2 rows are not safely comparable across share classes.
13D/G row: Roger M. Klein
Quick read
Roger M. Klein leads the comparable SEC ownership view at 10%.
4 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Roger M. Klein's linked filing trail.
Comparable ownership
Top 4
Roger M. Klein
10%
Bleichroeder LP
10%
Laurence W. Lytton
3.9%
MORGAN STANLEY
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Roger M. Klein |
3/4/5
13D/G
10%+ Owner · Klein Roger M.
|
10%
from 13D/G
|
$1,640,303
154,000 shares
|
-$95,885 | 06 Nov 2025 |
| Bleichroeder LP |
13D/G
|
10%
|
$63,223
158,058 shares
|
$0 | 24 Mar 2025 |
| Laurence W. Lytton |
13D/G
Lytton, Laurence W.
|
3.9%
|
$158,087
61,274 shares
|
$0 | 31 Mar 2025 |
| MORGAN STANLEY |
13D/G
|
0%
|
$331
31 shares
|
-$1,749,814 | 30 Nov 2025 |
| Ann D. Rhoads |
3/4/5
Director
|
—
class O/S missing
|
—
61,750 shares
|
— | 05 May 2021 |
| David A. Gonyer |
3/4/5
CEO, Director
|
—
class O/S missing
|
—
30,000 shares
|
— | 08 Feb 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$95,885.
Buys
$0
Insiders: 0
Sells
$95,885
Insiders: 1
Net
-$95,885
Shares: -9,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 9,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 9,000 | $0 | $95,885 | -$95,885 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Evoke Pharma Inc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Roger M. Klein
Net 12M change
-$95,885
Latest report
17 Dec 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Roger M. Klein | 10%+ Owner | $1,640,303 | -$95,885 | -5.5% | Filing P/S | 06 Nov 2025 |
| Mark Kowieski | Chief Financial Officer | $0 | Mixed | 16 Dec 2025 | ||
| Nantahala Capital Management, LLC | 10%+ Owner | $0 | Mixed | 17 Dec 2025 | ||
| Todd C. Brady | Director | $0 | Mixed | 16 Dec 2025 | ||
| Marilyn R. Carlson | Chief Medical Officer | $0 | Mixed | 16 Dec 2025 | ||
| Malcolm R. Hill | Director | $0 | Mixed | 16 Dec 2025 | ||
| Matthew J. D'Onofrio | Chief Executive Officer, Director | $0 | Mixed | 16 Dec 2025 | ||
| Cam L. Garner | Director | $0 | Mixed | 16 Dec 2025 | ||
| WIDDER KENNETH J | Director | Mixed | 17 Dec 2025 | |||
| Benjamin C. Smeal | Director | Mixed | 17 Dec 2025 | |||
| Ann D. Rhoads | Director | Mixed | 05 May 2021 | |||
| Greg Pyszczymuka | Director | Mixed | 17 Dec 2025 | |||
| David A. Gonyer | CEO, Director | Mixed | 08 Feb 2023 | |||
| Vickie S. Reed | Director | Mixed | 17 Dec 2025 |
Recent insider transactions for Evoke Pharma Inc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | EVOK | Common Stock | Other | -100% | -148,153 | 0 | 17 Dec 2025 | See Footnote | ||
| Nantahala Capital Management, LLC | EVOK | Amended Series C Common Stock Purchase Warrants | Other | -100% | -250,627 | 0 | 17 Dec 2025 | See Footnote | ||
| Nantahala Capital Management, LLC | EVOK | Amended Series A Common Stock Purchase Warrants | Other | -100% | -158,531 | 0 | 17 Dec 2025 | See Footnote | ||
| Nantahala Capital Management, LLC | EVOK | Series C Common Stock Purchase Warrants | Other | -100% | -117,019 | 0 | 17 Dec 2025 | See Footnote | ||
| Nantahala Capital Management, LLC | EVOK | Series A Common Stock Purchase Warrants | Other | -100% | -117,019 | 0 | 17 Dec 2025 | See Footnote | ||
| Nantahala Capital Management, LLC | EVOK | Prefunded Warrants | Other | -100% | -433,962 | 0 | 17 Dec 2025 | See Footnote | ||
| Greg Pyszczymuka | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -6,988 | 0 | 17 Dec 2025 | Direct | ||
| Benjamin C. Smeal | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -6,958 | 0 | 17 Dec 2025 | Direct | ||
| Marilyn R. Carlson | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -28,291 | 0 | 17 Dec 2025 | Direct | ||
| Cam L. Garner | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -11,520 | 0 | 17 Dec 2025 | Direct | ||
| Malcolm R. Hill | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -8,269 | 0 | 17 Dec 2025 | Direct | ||
| Mark Kowieski | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -30,291 | 0 | 17 Dec 2025 | Direct | ||
| Widder Kenneth J | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -8,207 | 0 | 17 Dec 2025 | Direct | ||
| Todd C. Brady | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -8,238 | 0 | 17 Dec 2025 | Direct | ||
| Vickie S. Reed | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -8,333 | 0 | 17 Dec 2025 | Direct | ||
| Matthew J. D'Onofrio | EVOK | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -134,840 | 0 | 17 Dec 2025 | Direct | ||
| Marilyn R. Carlson | EVOK | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -360 | 0 | 16 Dec 2025 | Direct | ||
| Cam L. Garner | EVOK | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -2,330 | 0 | 16 Dec 2025 | By Garner Investments, L.L.C. | ||
| Malcolm R. Hill | EVOK | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -133 | 0 | 16 Dec 2025 | Direct | ||
| Mark Kowieski | EVOK | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -11,815 | 0 | 16 Dec 2025 | Direct | ||
| Todd C. Brady | EVOK | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -27 | 0 | 16 Dec 2025 | Direct | ||
| Matthew J. D'Onofrio | EVOK | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -15,509 | 0 | 16 Dec 2025 | Direct | ||
| Roger M. Klein | EVOK | Common Stock | Sale | -3.1% | $42,600 | $10.65 | -4,000 | 125,000 | 06 Nov 2025 | By Krieger Charitable Trust |
| Roger M. Klein | EVOK | Common Stock | Sale | -14.7% | $53,285 | $10.66 | -5,000 | 29,000 | 06 Nov 2025 | By IRA |
* marks a reported price that did not pass the local price check.